Featured Research

from universities, journals, and other organizations

Breast cancer recurrence defined by hormone receptor status

Date:
October 1, 2012
Source:
BioMed Central Limited
Summary:
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity.

Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity.

Related Articles


Breast cancer is a heterogeneous disease with many different subtypes. HR positive cancer is more likely to be luminal A or B type and be treated with endocrine therapy including tamoxifen or aromatase inhibitors, while HR negative cancer is more likely to be basal or 'HER2-enriched'. HER2 positive cancers can fall into both of these categories.

A multicentre study from 13 National Comprehensive Cancer Network (NCCN) hospitals analysed data from over 3000 women diagnosed with early stage HER2 positive breast cancer. At first recurrence, most of the women in the study were treated with chemotherapy and/or with anti-HER2 therapy.

Dr Ines Vaz-Luis, who led the study revealed, "In this large group of patients with HER2 positive breast cancer, we found significant associations between presence of HR and presenting features, patterns of recurrence and survival outcomes. In the first five years after treatment more women died from HR negative cancer than HR positive." Recurrence in the brain or bone was also linked to receptor status, with more HR negative cancer in the brain and HR positive cancer in bone. About half of recurrent tumours tested had switched progesterone or estrogen receptor status (positive to negative or vice versa) or lost HER2 status during the study.

Dr Vaz-Luis, continued, "Based on our findings, HR status defines two different subsets of HER2 positive cancers. To combat this, we believe that studies which look at new drugs for treating HER2-positive breast cancer should also integrate hormone receptor status into their design."


Story Source:

The above story is based on materials provided by BioMed Central Limited. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ines Vaz-Luis, Rebecca A Ottesen, Melissa E Hughes, P Kelly Marcom, Beverly Moy, Hope S Rugo, Richard L Theriault, John Wilson, Joyce C Niland, Jane C Weeks, Nancy U Lin. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Research, 2012; 14 (5): R129 DOI: 10.1186/bcr3324

Cite This Page:

BioMed Central Limited. "Breast cancer recurrence defined by hormone receptor status." ScienceDaily. ScienceDaily, 1 October 2012. <www.sciencedaily.com/releases/2012/10/121001083650.htm>.
BioMed Central Limited. (2012, October 1). Breast cancer recurrence defined by hormone receptor status. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2012/10/121001083650.htm
BioMed Central Limited. "Breast cancer recurrence defined by hormone receptor status." ScienceDaily. www.sciencedaily.com/releases/2012/10/121001083650.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins